BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 28934212)

  • 21. Etiologic heterogeneity of clear-cell and papillary renal cell carcinoma in the Netherlands Cohort Study.
    van de Pol JAA; George L; van den Brandt PA; Baldewijns MMLL; Schouten LJ
    Int J Cancer; 2021 Jan; 148(1):67-76. PubMed ID: 32638386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
    Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
    Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
    Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
    Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.
    Douglas ML; Richardson MM; Nicol DL
    Cancer; 2004 May; 100(10):2118-24. PubMed ID: 15139053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.
    Steffens S; Janssen M; Roos FC; Becker F; Schumacher S; Seidel C; Wegener G; Thüroff JW; Hofmann R; Stöckle M; Siemer S; Schrader M; Hartmann A; Kuczyk MA; Junker K; Schrader AJ
    Eur J Cancer; 2012 Oct; 48(15):2347-52. PubMed ID: 22698386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early-stage clear cell tubulopapillary renal cell carcinoma: imaging features and distinction from clear cell and papillary subtypes.
    Mnatzakanian GN; Shinagare AB; Sahni VA; Hirsch MS; Silverman SG
    Abdom Radiol (NY); 2016 Nov; 41(11):2187-2195. PubMed ID: 27383741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus.
    Tilki D; Nguyen HG; Dall'Era MA; Bertini R; Carballido JA; Chromecki T; Ciancio G; Daneshmand S; Gontero P; Gonzalez J; Haferkamp A; Hohenfellner M; Huang WC; Koppie TM; Lorentz CA; Mandel P; Martinez-Salamanca JI; Master VA; Matloob R; McKiernan JM; Mlynarczyk CM; Montorsi F; Novara G; Pahernik S; Palou J; Pruthi RS; Ramaswamy K; Rodriguez Faba O; Russo P; Shariat SF; Spahn M; Terrone C; Vergho D; Wallen EM; Xylinas E; Zigeuner R; Libertino JA; Evans CP
    Eur Urol; 2014 Sep; 66(3):577-83. PubMed ID: 23871402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
    Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
    BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer.
    Chandarana H; Rosenkrantz AB; Mussi TC; Kim S; Ahmad AA; Raj SD; McMenamy J; Melamed J; Babb JS; Kiefer B; Kiraly AP
    Radiology; 2012 Dec; 265(3):790-8. PubMed ID: 23175544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.
    Zucchi A; Novara G; Costantini E; Antonelli A; Carini M; Carmignani G; Cosciani Cunico S; Fontana D; Longo N; Martignoni G; Minervini A; Mirone V; Porena M; Roscigno M; Schiavina R; Simeone C; Simonato A; Siracusano S; Terrone C; Ficarra V
    BJU Int; 2012 Apr; 109(8):1140-6. PubMed ID: 21871053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor.
    Mai KT; Landry DC; Robertson SJ; Commons AS; Burns BF; Thijssen A; Collins J
    Pathol Res Pract; 2001; 197(10):671-5. PubMed ID: 11700888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of three-dimensional tumor volume on cancer-specific survival for patients with pT1 clear-cell renal cell carcinoma.
    Song W; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    World J Urol; 2016 Jan; 34(1):83-8. PubMed ID: 25981404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
    Dudani S; de Velasco G; Wells JC; Gan CL; Donskov F; Porta C; Fraccon A; Pasini F; Lee JL; Hansen A; Bjarnason GA; Beuselinck B; Pal SK; Yuasa T; Kroeger N; Kanesvaran R; Reaume MN; Canil C; Choueiri TK; Heng DYC
    JAMA Netw Open; 2021 Jan; 4(1):e2021869. PubMed ID: 33475752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiating papillary type I RCC from clear cell RCC and oncocytoma: application of whole-lesion volumetric ADC measurement.
    Paschall AK; Mirmomen SM; Symons R; Pourmorteza A; Gautam R; Sahai A; Dwyer AJ; Merino MJ; Metwalli AR; Linehan WM; Malayeri AA
    Abdom Radiol (NY); 2018 Sep; 43(9):2424-2430. PubMed ID: 29520425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Papillary type 2 versus clear cell renal cell carcinoma: Survival outcomes.
    Simone G; Tuderti G; Ferriero M; Papalia R; Misuraca L; Minisola F; Costantini M; Mastroianni R; Sentinelli S; Guaglianone S; Gallucci M
    Eur J Surg Oncol; 2016 Nov; 42(11):1744-1750. PubMed ID: 27593224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological and immunohistochemical characteristics of papillary renal cell carcinoma with emphasis on subtyping.
    Alomari AK; Nettey OS; Singh D; Kluger H; Adeniran AJ
    Hum Pathol; 2015 Oct; 46(10):1418-26. PubMed ID: 26239624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
    Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
    Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
    Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
    Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome.
    Cornejo KM; Dong F; Zhou AG; Wu CL; Young RH; Braaten K; Sadow PM; Nielsen GP; Oliva E
    Hum Pathol; 2015 Oct; 46(10):1411-7. PubMed ID: 26297250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.